Unexpected exacerbation of Crohn's disease following treatment with human anti-IL-17A monoclonal antibody in patients with inflammatory bowel disease and de novo onset of inflammatory bowel diseases in psoriatic patients following anti-IL-17 antibody therapy support a gut-protective role of IL-17 even in humans (72, 73). The gene discussed is IL17A; the disease is inflammatory bowel disease.